SML2475

Larazotide acetate salt

≥95% (HPLC)

• Synonym(e): AT-1001, AT1001, GGVLVQPG acetate, Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-glycine acetate
• Empirische Formel (Hill-System): C₃₂H₅₅N₉O₁₀ · xC₂H₄O₂
• CAS-Nummer: 881851-50-9
• Molekulargewicht: 725.83 (free base basis)
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Assay: ≥95% (HPLC)
• Form: powder
• Farbe: white to beige
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• SMILES String: N1([C@@H](CCC1)C(=O)NCC(=O)O)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)CC(C)C)C(C)C)CCC(=O)N.OC(=O)C
• InChI: 1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(
• InChIKey: NYGCNONRVCGHAT-UFIKZEAMSA-N

Beschreibung

Biochem./physiol. Wirkung

Larazotide acetate (AT1001) is a Zonulin receptor antagonist, a tight junction modulator. Larazotide inhibition of zonulin results in reducing trafficking across epithelial cells in the intestines and reducing intestinal permeability and "leaky gut," thought to be a gateway to multiple autoimmune diseases, including celiac disease, irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD, Crohn′s and ulcerative colitis), type 1 diabetes mellitus (T1DM), nonalcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and several others. It has been shown to inhibit the effect of inflammatory cytokines such as tumor necrosis factor (TNF-alpha) and interleukin (IL-4), blocking their increase of intestinal epithelial permeability.

Zonulin receptor antagonist; tight junction modulator

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable